Faron’s Post

Reminder to come by Plus Therapeutics at the SNMMI 2024 Annual Meeting in Toronto at Booth #1948 Learn about the latest ReSPECT-LM Clinical Trial data for Leptomeningeal Metastases and view our newest poster in the poster hall Two accepted abstracts titled: 1) "Rhenium (186Re) obisbemeda (186RNL) in leptomeningeal metastases (LM) Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility through Cohorts 1-4" 2) "Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastasis Using Beta-Emission Radiopharmaceuticals" Posters will be available on https://lnkd.in/eQXB5zz5 after the conference. #SNMMI #BrainCancer #Glioblastoma #BreastCancer #LungCancer #Melanoma #ClinicalTrials 

At Society for Neuro-Oncology Annual in Houston: Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases > Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints > CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases > Assay demonstrated 2.8 times the diagnostic sensitivity vs. standard cytology Full details: https://bit.ly/4g01bdb #SNO2024

ConcertAI and NeoGenomics Laboratories are excited announce CTO-H, a joint data-as-a-service and software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization! CTO-H provides a research data solution that is unprecedented in its scale, longitudinality, and biomarker depth. This announcement is a major outcome of the collaboration jointly announced on Jan. 8, 2024 – hear more at the 2024 American Society of Hematology (ASH) Meeting in San Diego. Read more: https://hubs.ly/Q02-w76R0 Meet with us at ASH 2024: https://hubs.ly/Q02-LFb30 #HematologyInnovation #AIinHealthcare #ClinicalTrials #OncologyData #ASH24

Another good news from #ASH24 A landmark analysis of the phase III GMMG-HD7 trial assessing the impact of induction regimen and post-induction and post-transplant MRD on PFS. Post-induction and post-transplantation MRD negativity led to better outcomes in both the Isatuximab-RVd and RVd arms, and Isa-RVd was associated with a PFS benefit vs RVd in MRD+ patients. American Society of Hematology International Myeloma Foundation Controversies in Multiple Myeloma (COMy)

Alentis's first in class antibody, Lixudebart, targeted against Claudin1 continues to make very good progress in ANCA associated vasculitis and advanced liver fibrosis.

Excited to be sharing topline results for two clinical trials of lixudebart (ALE.F02) in patients with ANCA-associated vasculitis with RPGN (Phase 2) and advanced liver fibrosis (Phase 1b). In both studies, lixudebart demonstrated: ·      Robust dose-dependent target engagement ·      Preliminary evidence of improved organ function: eGFR and proteinuria in ANCA-RPGN, and an initial decrease in ALT/AST in liver fibrosis ·      A favorable safety profile Lixudebart is a monoclonal antibody targeting Claudin-1 (#CLDN1), developed to reverse organ fibrosis. Read the full press release: https://lnkd.in/ecMmPPpr #AlentisTherapeutics #Claudin #KidneyFibrosis #Fibrosis #ANCAVasculitis #LiverFibrosis #ToplineResults #ClinicalTrial

Do carve out time in your busy schedule to meet Jennell and learn about RBC health biomarkers.

We are very excited to have SLS009, our highly selective CDK9 inhibitor, featured at the 2024 ASH meeting - treatment with SLS009 in combination with aza-ven was well tolerated and led to a 50% response rate in the selected optimal dose. Clinical activity was even higher in patients with AML-myelodysplasia-related changes, and particularly those with ASXL1 mutations, suggesting that this subset of patients may exhibit preferential sensitivity to SLS009. The 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Survival (OS) of 5.5 Months vs. <2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg BIW Median OS Not Reached. More updates to come this Q! SELLAS Life Sciences Group, Inc. American Society of Hematology American Society of Clinical Oncology (ASCO) European Hematology Association (EHA) European School of Haematology (ESH) https://lnkd.in/eTAQHWmP

🌟 Publication Alert! 🌟   We are thrilled to share a recent peer-reviewed study published in the International Journal of Laboratory Hematology, titled “Metrological traceability in flow cytometry? Evaluation of a new volumetric method for lymphocyte subsets”.   🔍 𝗠𝗲𝘁𝗵𝗼𝗱: The study compares the traditional bead-based technique with the volumetric method on the Sysmex XF-1600 flow cytometer for lymphocyte subset enumeration using the Sysmex KOMBITEST TBNK 6-color test system.   📊 𝗢𝘂𝘁𝗰𝗼𝗺𝗲: The results indicate a high degree of correlation between both methodologies, with biases within clinically acceptable limits.   📌 𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻: The study highlights the importance of precise lymphocyte enumeration and the value of innovative technologies in clinical practice. This research underscores the robustness and clinical reliability of metrologically traceable lymphocyte subset counts produced by XF-1600 flow cytometer using the Sysmex KOMBITEST TBNK 6-color test system.   📖 Read the full article here: https://lnkd.in/er9X-jKQ   #FlowCytometry #ClinicalResearch #Sysmex

At Society for Neuro-Oncology Annual in Houston: Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases > CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions > CNSide identified extensive, actionable mutational changes, and clinically relevant longitudinal biomarkers Full details: https://bit.ly/3CDgzOk